A Phase I, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
Latest Information Update: 24 Sep 2024
Price :
$35 *
At a glance
- Drugs AZD 0780 (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Sep 2024 New trial record